Ying Liang

Ying Liang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2024 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
XWXieraili Wumener
Xieraili Wumener
YZYarong Zhang
Yarong Zhang
ZZZihan Zang
Zihan Zang
FDFen Du
Fen Du
XYXiaoxing Ye
Xiaoxing Ye
YLYing Liang
Ying Liang
Objectives: 18F-fluorodeoxyglucose (FDG) PET/CT has been widely used for the differential diagnosis of cancer. Semi-quantitative standardized uptake value (SUV) is known to be affected by multiple factors and may make it difficult to differentiate between benign and malignant lesions. It is crucial to find reliable quantitative metabolic parameters to further support the diagnosis. This study aims to evaluate the value of the quantitative metabolic parameters derived from dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting epidermal growth factor receptor (EGFR) mutation status. Methods: We included 147 patients with lung lesions to perform FDG PET/CT dynamic plus static imaging with informed consent. Based on the results of the postoperative pathology, the patients were divided into benign/malignant groups, adenocarcinoma (AC)/squamous carcinoma (SCC) groups, and EGFR-positive (EGFR+)/EGFR-negative (EGFR-) groups. Quantitative parameters including K1, k2, k3, and Ki of each lesion were obtained by applying the irreversible two-tissue compartmental modeling using an in-house Matlab software. The SUV analysis was performed based on conventional static scan data. Differences in each metabolic parameter among the group were analyzed. Wilcoxon rank-sum test, independent-samples T-test, and receiver-operating characteristic (ROC) analysis were performed to compare the diagnostic effects among the differentiated groups. P < 0.05 were considered statistically significant for all statistical tests. Results: In the malignant group (N = 124), the SUVmax, k2, k3, and Ki were higher than the benign group (N = 23), and all had-better performance in the differential diagnosis (P < 0.05, respectively). In the AC group (N = 88), the SUVmax, k3, and Ki were lower than in the SCC group, and such differences were statistically significant (P < 0.05, respectively). For ROC analysis, Ki with cut-off value of 0.0250 ml/g/min has better diagnostic specificity than SUVmax (AUC = 0.999 vs. 0.70). In AC group, 48 patients further underwent EGFR testing. In the EGFR (+) group (N = 31), the average Ki (0.0279 ± 0.0153 ml/g/min) was lower than EGFR (-) group (N = 17, 0.0405 ± 0.0199 ml/g/min), and the difference was significant (P < 0.05). However, SUVmax and k3 did not show such a difference between EGFR (+) and EGFR (-) groups (P>0.05, respectively). For ROC analysis, the Ki had a cut-off value of 0.0350 ml/g/min when predicting EGFR status, with a sensitivity of 0.710, a specificity of 0.588, and an AUC of 0.674 [0.523–0.802]. Conclusion: Although both techniques were specific, Ki had a greater specificity than SUVmax when the cut-off value was set at 0.0250 ml/g/min for the differential diagnosis of lung cancer. At a cut-off value of 0.0350 ml/g/min, there was a 0.710 sensitivity for EGFR status prediction. If EGFR testing is not available for a patient, dynamic imaging could be a valuable non-invasive screening method.

14 November 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
QWQiong Wang
Qiong Wang
ZLZhongjing Li
Zhongjing Li
YHYong Huang
Yong Huang
CLChengze Li
Chengze Li
YLYiluo Li
Yiluo Li
YLYing Liang
Ying Liang

4 April 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
ZYZhiheng Yao
Zhiheng Yao
YWYubo Wang
Yubo Wang
YWYaping Wu
Yaping Wu
JZJinpeng Zhou
Jinpeng Zhou
NDNa Dang
Na Dang
TSTao Sun
Tao Sun
Background Dynamic 18F-fluorodeoxyglucose (18F-FDG) PET/CT imaging has been shown to provide additional information for diagnosing lung cancer. The aim of this study was to investigate whether metabolic and flow features directly extracted from time activity curves (TACs) help differentiate between benign and malignant conditions of lung lesions. Methods TACs at the primary lesion were extracted from each dynamic 18F-FDG PET/CT scan. The TAC signal was then decomposed into metabolism and blood flow components through kinetic modeling. Dynamic features including area under the curve (AUC), time-to-peak, and slopes were then extracted from each component. The extracted features from 187 patients (mean age, 60.41 ± 11.01 years; 117 males) were used to train a classification model based on bagging, a machine-learning method built with decision trees. The performance of the trained model on differentiating benign and malignant was tested using receiver operating characteristic analysis with cross-validation. External testing was then performed for an independent dataset that consisted of 42 dynamic scans. For the results, SHapley Additive exPlanations (SHAP) were used to assess the relative importance of the contributed features for individuals. Waterfall charts were also plotted, together with assessment of Cohen’s effect size to demonstrate the superiority of the proposed model over SUVmax and the net FDG influx rate Ki. Results The combination of the multiple dynamic features was able to separate benign and malignant lesions. For cross-validation, the trained model had an AUC of 0.89, sensitivity of 0.80, and specificity of 0.88, which was significantly higher than that of either SUVmax (AUC = 0.79, DeLong p < 0.001) or Ki (AUC = 0.76, DeLong test p < 0.001). For the testing dataset, the model had an AUC of 0.86, which again was better than either SUVmax (AUC of 0.72) or Ki (AUC of 0.71). The most important features that contributed to the diagnosis identified by SHAP included the slope and maximum metabolism TAC at the lesion, the AUC, and the peak time of blood TAC at the lesion. The waterfall chart illustrated that the model had significantly different prediction scores between the benign and malignant groups (p < 0.001) with a Cohen’s effect size of 1.71, which was higher than that of the values for SUV and Ki (Cohen’s effect size 0.96 and 0.81, respectively). Conclusion An explainable machine learning model that combines dynamic FDG metabolic and flow features can predict benign or malignant lung cancer patients more accurately than conventional parameters such as SUVmax or net influx rate Ki.

1 January 2025 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
XWXieraili Wumener
Xieraili Wumener
XYXiaoxing Ye
Xiaoxing Ye
YZYarong Zhang
Yarong Zhang
TETuya E
Tuya E
JZJiuhui Zhao
Jiuhui Zhao
JZJun Zhao
Jun Zhao
Background: SMARCA4/BRG1-deficient non-small cell lung cancer (S/B-d NSCLC) is a rare subtype of non-small cell lung cancer (NSCLC). The aim of this study was to investigate the clinical, imaging, serum tumor marker, and pathological features of S/B-d NSCLC, particularly computed tomography (CT) and 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) scan features. Methods: Our analysis included 23 patients with pathologically confirmed S/B-d NSCLC from January 2021 to December 2023. A retrospective analysis of clinical, serum tumor markers, imaging [including CT, FDG PET/CT, magnetic resonance imaging (MRI)], pathological features, treatment protocols, and follow-up results was performed. Independent samples t-tests were used to assess statistical differences in short diameters and maximum standardized uptake value (SUVmax) between groups. Results: S/B-d NSCLC occurs predominantly in male patients with a history of smoking and a mean age of 62.78 years (39–77 years). S/B-d NSCLC was found incidentally during physical examination in 56.52% of patients. The CT scan features were as follows: predominantly tumors (72.73%), peripheral in the lungs (77.27%), round or roundish morphology (81.28%), pleural or vascular invasion (95.46%), and moderately to severely enhanced (59.09%). The FDG PET/CT showed FDG-avid with mean SUVmax of 14.78±9.57. Lung cancer-related serum tumor markers had high positivity rates for carcinoembryonic antigen (CEA) (66.67%), recombinant cytokeratin fragment antigen 21-1 (CYFRA21-1) (61.91%), and carbohydrate antigen 125 (CA125) (57.14%). Pathological features are often characterized by grading (poor differentiation, 100%), tumor spread through the air space (STAS, 85.71%), and vascular invasion (85.71%). Immunohistochemistry showed that SMARCA4 (BRG1) was absent, and P40, P63, ALK-Ventana ALK (D5F3), and p-TRK were often negative. Genetic tests showed that the positivity rate of TP53 (76.92%) and KEAP1 (53.85%) was high. Despite diverse treatment options being available, high rates of progression during treatment and poor prognosis were observed. Among CT features (N=22), the short diameter of CT-diagnosed metastatic lymph nodes (LNs) was larger than that of non-metastatic LNs, and the difference was statistically significant (P=0.02). Among the FDG PET/CT features (N=12), SUVmax was larger in tumor group than lesion group, SUVmax was larger in M1 group than M0 group, and the difference was statistically significant in both groups (P=0.001 and P=0.04). Conclusions: S/B-d NSCLC has distinct features in epidemiology, serum tumor markers, imaging, and pathology. In particular, FDG-avid is evident in the FDG PET/CT scan. The size of the lesion and the degree of FDG avidity provide information about the degree of malignancy and the high probability of distant metastasis in S/B-d NSCLC. FDG PET/CT is recommended when S/B-d NSCLC is suspected based on CT features, especially for large lesions. The FDG PET/CT scan can help with accurate staging and individual treatment planning.

13 June 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
XWXieraili Wumener
Xieraili Wumener
XYXiaoxing Ye
Xiaoxing Ye
YZYarong Zhang
Yarong Zhang
SJShi Jin
Shi Jin
YLYing Liang
Ying Liang
SMARCA4-deficient non-small cell lung cancer (NSCLC) is a more recently recognized subset of NSCLC. We describe the 18F-fluorodeoxyglucose (FDG) PET/CT findings in a rare case of SMARCA4-deficient NSCLC and response to therapy. A 45-year-old male patient with a history of heavy smoking (10 years) underwent an 18F-fluorodeoxyglucose (FDG) PET/CT dynamic (chest) + static (whole-body) scan for diagnosis and pre-treatment staging. 18F-FDG PET/CT showed an FDG-avid mass in the upper lobe of the left lung (SUVmax of 22.4) and FDG-avid lymph nodes (LN) in the left pulmonary hilar region (SUVmax of 5.7). In addition, there were multiple metastases throughout the body, including in the distant LNs, adrenal glands, bone, left subcutaneous lumbar region, and brain. Pathological findings confirmed SMARCA4-deficient NSCLC. After four cycles of chemotherapy and immune checkpoint inhibitors (ICI), the patient underwent again an 18F-FDG PET/CT scan (including a dynamic scan) for efficacy evaluation. We report a case that deepens the understanding of the 18F-FDG PET/CT presentation of SMARCA4-deficient NSCLC as well as dynamic imaging features and parametric characteristics.

5 March 2024 in EJNMMI Physics
Verified
Journal Article
Open access
PDF file
FDFen Du
Fen Du
XWXieraili Wumener
Xieraili Wumener
YZYarong Zhang
Yarong Zhang
MZMaoqun Zhang
Maoqun Zhang
JZJiuhui Zhao
Jiuhui Zhao
YLYing Liang
Ying Liang
Purpose: This study aimed to evaluate the clinical feasibility of early 30-minute dynamic 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) positron emission tomography (PET) scanning protocol for patients with lung lesions in comparison to the standard 65-minute dynamic FDG-PET scanning as a reference. Methods: Dynamic 18F-FDG PET images of 146 patients with 181 lung lesions (including 146 lesions confirmed by histology) were analyzed in this prospective study. Dynamic images were reconstructed into 28 frames with a specific temporal division protocol for the scan data acquired 65 min post-injection. Ki images and quantitative parameters Ki based on two different acquisition durations [the first 30 min (Ki-30 min) and 65 min (Ki-65 min)] were obtained by applying the irreversible two-tissue compartment model using in-house Matlab software. The two acquisition durations were compared for Ki image quality (including visual score analysis and number of lesions detected) and Ki value (including accuracy of Ki, the value of differential diagnosis of lung lesions and prediction of PD-L1 status) by Wilcoxon’s rank sum test, Spearman’s rank correlation analysis, receiver operating characteristic (ROC) curve, and the DeLong test. The significant testing level (alpha) was set to 0.05. Results: The quality of the Ki-30 min images was not significantly different from the Ki-65 min images based on visual score analysis (P > 0.05). In terms of Ki value, among 181 lesions, Ki-65 min was statistically higher than Ki-30 min (0.027 ± 0.017 ml/g/min vs. 0.026 ± 0.018 ml/g/min, P < 0.05), while a very high correlation was obtained between Ki-65 min and Ki-30 min (r = 0.977, P < 0.05). In the differential diagnosis of lung lesions, ROC analysis was performed on 146 histologically confirmed lesions, the area under the curve (AUC) of Ki-65 min, Ki-30 min, and SUVmax was 0.816, 0.816, and 0.709, respectively. According to the Delong test, no significant differences in the diagnostic accuracies were found between Ki-65 min and Ki-30 min (P > 0.05), while the diagnostic accuracies of Ki-65 min and Ki-30 min were both significantly higher than that of SUVmax (P < 0.05). In 73 (NSCLC) lesions with definite PD-L1 expression results, the Ki-65 min, Ki-30 min, and SUVmax in PD-L1 positivity were significantly higher than that in PD-L1 negativity (P < 0.05). And no significant differences in predicting PD-L1 positivity were found among Ki-65 min, Ki-30 min, and SUVmax (AUC = 0.704, 0.695, and 0.737, respectively, P > 0.05), according to the results of ROC analysis and Delong test. Conclusions: This study indicates that an early 30-minute dynamic FDG-PET acquisition appears to be sufficient to provide quantitative images with good-quality and accurate Ki values for the assessment of lung lesions and prediction of PD-L1 expression. Protocols with a shortened early 30-minute acquisition time may be considered for patients who have difficulty with prolonged acquisitions to improve the efficiency of clinical acquisitions.